Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Freight, not feedstock, that's been driving Levetiracetam higher, with Germany feeling it the most. The prices there rose by 2.8% in the first half of 2026 (H1 2026), from a value of USD 32.7/KG to USD 33.6/KG, the highest of all the tracked markets. The persistent import cost inflation and elevated container freight rates from Asia kept the European landed costs up. A firm pharmaceutical manufacturing demand added to the pressure further. Globally, the prices moved from a value of USD 29.86/KG to USD 30.66/KG, a smaller gain of 2.7 percent. Expect a range of USD 31-34/KG for the second half of 2026 (H2 2026). The ageing demographics and hospital restocking ahead of tender cycles are both continuing at their current pace.
Levetiracetam is a pyrrolidine derivative anticonvulsant, made through a multi-step organic process from the pyrrolidinone intermediates, then resolved and purified to a pharmaceutical grade. What sets it apart pharmacologically is a distinct mechanism. It suppresses the hypersynchronised epileptiform burst firing through a high-affinity binding to the synaptic vesicle protein 2A. It doesn't touch the normal neuronal transmission the way other antiepileptic drugs can. The epilepsy and seizure disorder treatment absorbs the overwhelming share of the demand, covering the partial-onset seizures, myoclonic seizures, and primary generalised tonic-clonic seizures across oral tablets, intravenous injections, and oral solutions. The contract manufacturing for generic formulations makes up the rest. The acetonitrile and pyrrolidinone feedstock costs set the baseline. The container freight and exporter allocation conditions add on top of that. The hospital tender cycle timing determines how much gets passed through in any given quarter.
Logistics, not chemistry, that's the driver heading into the second half of 2026 (H2 2026), worth keeping in mind when reading the forecast. The hospital and pharmaceutical manufacturing buyers restocked ahead of the tender cycles through the H1, tracking the ageing demographic trends that sustain the baseline epilepsy treatment demand fairly predictably. The container freight rates and exporter cargo allocations from India and Spain firmed gradually. That kept the production floor well supported.
Tighter export allocations, or a sharp container freight cost spike, could push the prices above the band. A softer hospital restocking, or an easing of the current freight pressures, would work the other way around.
| Region | 2026 Price Range (USD/KG) | Outlook |
| Global Average | 31 - 34 | Hospital restocking and export allocation support |
| United States | 31 - 34 | Freight and tightening allocations maintain firm pricing |
| China | 27 - 30 | Export capacity keeps China most affordable |
| Germany | 32 - 36 | Import cost inflation supports the highest premium |
| India | 29 - 32 | Steady export demand supports firm middle |
The US prices rose by 2.8% to a value of USD 32.5/KG. The elevated container freight rates from Asia kept the landed costs firm. A steady hospital restocking demand meant there was little to push against that pressure.
Why did the price of Levetiracetam change in Q2 2026 in the United States?
Elevated container freight rates from Asia kept landed costs firm throughout the quarter. Steady pharmaceutical procurement ahead of tender cycles supported buying regardless. Constrained cargo allocations from key exporting regions added a bit more pressure near USD 32.5/KG.
China rose by 2.5% to a value of USD 28.4/KG, still the cheapest tracked market. The rising export quotations reflected a firm downstream pharmaceutical demand. The stable natural gas input costs kept the move fairly measured overall.
Why did the price of Levetiracetam change in Q2 2026 in China?
Rising export quotations reflected firm downstream pharmaceutical demand this quarter. Stable Asian natural gas inputs limited how much cost pressure actually came through. Steady acetonitrile feedstock availability kept the increase measured near USD 28.4/KG.
Germany led every single tracked market at a value of USD 33.6/KG, up by 2.8%. The persistent import cost inflation is the recurring driver here. A firm pharmaceutical manufacturing demand keeps the European floor elevated.
Why did the price of Levetiracetam change in Q2 2026 in Germany?
Persistent import cost inflation elevated European landed costs through the quarter. Steady growth in Germany's pharmaceutical manufacturing sector sustained demand alongside that. Hamburg port efficiency and stable EUR-USD parity at least limited further volatility.
India rose by 2.7% to a value of USD 30.0/KG. Ample export volumes to Europe and other markets kept the supply flowing. A firm international demand pushed the market higher without any real supply disruption.
Why did the price of Levetiracetam change in Q2 2026 in India?
Ample export volumes to Europe and other regions kept supply flowing steadily through the quarter. Firm international demand from hospital and formulary buyers supported the increase. Disciplined exporter offers kept the market from rising any more sharply than it did.
The US prices rose by 1.9% to a value of USD 31.6/KG in Q1. The tightening exports and constrained cargo allocations from key producing regions supported the increase. That set up the continued gain into the Q2.
Why did the price of Levetiracetam change in Q1 2026 in the United States?
Tightening exports and constrained cargo allocations reduced import availability across major routes. Cautious procurement activity supported measured buying despite the tighter market. USD 31.6/KG is where things landed.
China's Q1 average rose by 2.2% to a value of USD 27.7/KG. Rising export quotations. Steady downstream pharmaceutical demand. Both supported the gradual increase, a fairly typical quarter overall.
Why did the price of Levetiracetam change in Q1 2026 in China?
Rising export quotations reflected steady downstream pharmaceutical demand throughout the quarter. Contained acetonitrile costs limited how much of that got passed through as higher prices. USD 27.7/KG is where the quarter closed.
Germany rose by 2.2% to a value of USD 32.7/KG in Q1. Persistent import cost inflation. Steady pharmaceutical manufacturing growth. Both supported the increase, the same pattern that intensified into the Q2.
Why did the price of Levetiracetam change in Q1 2026 in Germany?
Persistent import cost inflation raised European landed costs steadily through the quarter. Steady growth in domestic pharmaceutical manufacturing sustained demand alongside that. Market advanced to USD 32.7/KG.
India rose by 2.1% to a value of USD 29.2/KG in Q1. Steady export demand. Disciplined exporter offers. Both supported the increase, setting up the stronger gain that followed in the Q2.
Why did the price of Levetiracetam change in Q1 2026 in India?
Steady export demand from European and North American buyers supported consistent buying. Disciplined exporter offers kept pricing measured rather than volatile. USD 29.2/KG is where the quarter landed.
Every single quarter tracked here closed higher than the previous one. The driver stayed remarkably consistent throughout: the tightening exports and the rising freight costs, not feedstock shortages. From a value of USD 27.52/KG in Q1 2025 to USD 30.66/KG by Q2 2026, a cumulative gain of 11.4 percent. The container freight cost cycles and the exporter cargo allocation conditions explain nearly all of the movement.
| Quarter | Price (USD/KG) | QoQ Change | Direction |
| Q2 2026 | 30.66 | +2.7% | ↑ Rising |
| Q1 2026 | 29.86 | +2.1% | ↑ Rising |
| Q4 2025 | 29.24 | +1.8% | ↑ Rising |
| Q3 2025 | 28.72 | +2.4% | ↑ Rising |
| Q2 2025 | 28.06 | +2.0% | ↑ Rising |
| Q1 2025 | 27.52 | - | - Stable |
Steady climbing, that was the year 2025 for Levetiracetam, tightening exports plus rising freight costs behind essentially all of it. The global average opened at a value of USD 27.52/KG in Q1, closed at USD 29.24/KG in Q4, a gain of 6.3 percent. The elevated container freight rates from Asia, the constrained cargo allocations, and a cautious but consistent procurement activity from hospitals and manufacturers alongside, drove the sustained increase throughout the year.
The US prices rose by 6.2 percent, from a value of USD 29.2/KG to USD 31.0/KG. The rising export quotations from China, along with the elevated container freight rates, drove the sustained increase.
The Chinese prices climbed by 6.3 percent, from a value of USD 25.5/KG to USD 27.1/KG. The firm downstream pharmaceutical demand, along with the stable natural gas input costs, drove the increase.
The German prices posted the strongest gain of all four regions, at 6.7 percent, from a value of USD 30.0/KG to USD 32.0/KG. The persistent import cost inflation, along with a firm pharmaceutical demand, drove the year-long climb.
The Indian prices advanced by 5.9 percent, from a value of USD 27.0/KG to USD 28.6/KG. Ample export volumes to Europe and North America pushed the trend steadily higher.
Expert Market Research: Your Source for Real-Time Levetiracetam Price Intelligence
Expert Market Research tracks the Levetiracetam prices continuously, across every major producing and consuming region. The team traces the causation through the acetonitrile and pyrrolidinone feedstock economics, the container freight and exporter allocation cycles, and the shifting hospital and pharmaceutical manufacturing demand. Contact Expert Market Research today for the Levetiracetam pricing data, a bespoke market analysis, and a strategic procurement advisory.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
The epilepsy and seizure disorder treatment accounts for the overwhelming majority of the demand, covering the partial-onset seizures, myoclonic seizures, and primary generalised tonic-clonic seizures. The contract manufacturing for generic formulations makes up the rest.
The Q2 2026 prices come to a value of USD 32.5/KG in the United States, USD 28.4/KG in China, USD 33.6/KG in Germany, and USD 30.0/KG in India. The persistent import cost inflation keeps Germany at the top of the range.
The global average rose from a value of USD 29.24/KG in Q4 2025 to USD 29.86/KG in Q1 2026, then to USD 30.66/KG by Q2, a gain of 2.7 percent across the half-year. The tightening exports and rising freight costs drove the increase, extending a pattern that's held for well over a year now.
The tightening exports and higher freight expenses have constrained the cargo allocations across the major supply routes for several quarters running. A cautious but consistent procurement activity from hospitals and pharmaceutical manufacturers has sustained the demand throughout. The ageing demographics continue driving the baseline epilepsy treatment consumption regardless of what's happening on the supply side.
A range of USD 31 to 34/KG looks like the right one for the rest of the year 2026, assuming the hospital restocking ahead of tender cycles and the ageing-demographic demand hold at current levels.
Germany carries the highest cost, owing to the persistent import cost inflation. The United States holds a premium tied to the freight and tightening allocations. India sits in the middle, owing to the steady export demand. China prices the lowest, thanks to a substantial export capacity.
Monthly. Reach out to the Expert Market Research team directly for real-time pricing intelligence.
The acetonitrile and pyrrolidinone feedstock costs sit at the core of it, with the container freight rates and exporter cargo allocations close behind. The hospital tender cycles matter too, and the ageing demographic trends shape a sustained baseline demand across every major market.
India and Spain lead as major exporters, with China also contributing a significant export volume. Teva, Sun Pharmaceutical, Mylan, Dr. Reddy's, and Zydus Cadila are among the leading generic API and formulation manufacturers in this space.
Timing the hospital and pharmaceutical manufacturing contracts around the tender cycles and ageing-demographic demand growth is the main lever here. The container freight costs give the clearest signal for the near-term direction, and given how tight the export allocations have stayed, building in a forward coverage tends to be worth it.
One Year Subscription
One Year Subscription
USD 799
USD 699
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.